Цель обзора: представить новые подходы к терапии больных с хронической HCV-инфекцией, основанные на клиническом применении препарата прямого противовирусного действия Софосбувир. Основные положения: до недавнего времени стандартным подходом к лечению HCV-инфекции оставалось назначение схем на основе пегилированного интерферона (ПЭГ-ИФН) в комбинации с рибавирином. В последние годы препаратами выбора становятся средства узконаправленного воздействия на функциональные белки самого вируса-препараты прямого противовирусного действия, что значительно повышает эффективность и безопасность лечения. Препараты прямого противовирусного действия классифицируют по типу вирусных белков, которые служат мишенью их действия: ингибиторы протеаз (наименования препаратов оканчиваются на «-превир»), ингибиторы полимеразы (наименования препаратов оканчиваются на «-бувир»), ингибиторы NS5A (наименования препаратов оканчиваются на «-асвир»). Препарат Софосбувир-аналог уридинового нуклеотида, мощный ингибитор NS5B-ключевого фермента репликации HCV-РНК, широко применяется в различных схемах противовирусной терапии. Заключение: Софосбувир-один из наиболее многообещающих препаратов для лечения хронической HCV-инфекции. Его бесспорные преимущества: можно применять при различных генотипах вируса, декомпенсированной функции печени. Софосбувир отличается очень хорошей переносимостью и низкой вероятностью развития вирусной резистентности.
M.Sechenov First Moscow State Medical University of the Ministry of Health of Russia (Sechenov University) RABEPRAZOLE IN THE TREATMENT OF DUODENAL ULCER DESEASE AND FUNCTIONAL DYSPEPSIA The review aims to provide a contemporary view of the pathogenesis and treatment of the most common duodenum diseasesduodenal ulcer disease (DUD) and functional dyspepsia (FD).Due to its unique structure and functions, the duodenum that anatomically represents the initial section of the small intestine differentiates itself from others. The prevalence of DUD is declining in many Western countries due to the widespread introduction of effective anti-Helicobacter therapy and a significant decrease in the prevalence of H pylori infection. However, the ideas about the poly-biological nature of DUD persists and additional risk factors continue to be studied. DUD is manifested by pain/burning feeling in the epigastric region, as well as by symptoms such as early satiety, epigastric filling after eating in the absence of obvious organic changes in the digestive system. The diagnosis of FD is based on the Rome IV criteria. The duodenum plays an important role in its pathogenesis (disorders of gastric accommodation, motor and visceral hypersensitivity). Most patients with FD have microscopic signs of inflammation of the mucous membrane of the postbulbar part of the duodenum -an increased amount of intraepithelial lymphocytes, eosinophils, and signs of increased permeability of the mucous membrane. In all likelihood, these changes are provoked by infection and / or nutritional factors, as well as by exposure to hydrochloric acid. Proton pump inhibitors (prokinetics in postprandial distress syndrome) form the basis of treatment of peptic ulcer and epigastric pain syndrome; all patients with DUD and dyspepsia syndrome infected with H. pylori receive antihelicobacter therapy. Rabeprazole that is characterized by a long and powerful effect and minimal interaction with the cytochrome 2C19 system stands out from the proton pump inhibitors. Conclusion: acid aggression plays a very important role in the pathogenesis of duodenal ulcers diseases and FD; proton pump inhibitors form the basis for the treatment of such patients both in the form of monotherapy and as part of eradication regimens.
Introduction. Constipation is a derangement of the motor, secretory and/or evacuation function of the colon. The same symptoms are recorded in at least 20% of the population in the developed countries – as those occurring sporadically or for a long period.Basic content. The secretory function of the colon significantly affects stool consistency and its free movement. The secretion increases by 8–10 times in the presence of local mechanical irritation. Intestinal mucus is produced by colonic goblet cells. The frequency, time of defecation and stool consistency is in large part determined by the motor function of the colon. The relation of various types of contraction varies depending on the main function – propulsion or mixing. Rhythmic phasic contractions in the colon generate a pendular movement with slow propulsion of the contents and absorption of water. The tonic contractions enhance the mixing effect of weak rhythmic contractions. The propulsive contractions are specifically attributed to the lower gastrointestinal tract and occur spontaneously. They occur quite regularly, from 2 to 10 times a day, and ensure the propulsion of intestinal contents over great distances in the colon. When reaching the sphincter area, such wave causes its relaxation by mechanisms of descending inhibition. The dietary regime and adequate intake of carbohydrates with various chain lengths, including dietary fiber, as well as flavonoids and other components that modify peristaltic activity and secretion, play an important role in the regulation of intestinal secretion and peristalsis. The drugs enhancing intestinal secretion and peristalsis, such as bisacodyl and sodium picosulfate, are also used to treat constipation. These substances hydrolyse into bis-(p-hydroxyphenyl)-pyridyl-2-methane in the intestine, which, upon contact with the receptors in colonic mucosa, stimulates propulsive activity and increases intestinal secretion. The selective action of sodium picosulfate is confined to the colon.Conclusion. Pharmacological and non-pharmacological treatments for constipation are aimed at maintaining and enhancing the natural propulsive contractions of the colon and intestinal secretion.
В статье освещается одна из наиболее часто встречаемых патологий печени - неалкогольная жировая болезнь печени (НАЖБП), обсуждаются современные концепции этиологии, патогенеза, принципы диагностики и новейшие походы к консервативному и хирургическому лечению данного заболевания. Описывается патофизиология инсулинорезистентности, метаболического синдрома и ряда других клинически-ассоциированных с НАЖБП состояний. Подробно рассматриваются патогенетические аспекты развития фиброза при НАЖБП и описываются современные возможности и ограничения методов визуализации в диагностике степени стеатоза и стадии фиброза печени, ультразвукового исследования и сывороточных маркеров. Обоснованы подходы к обследованию и ведению пациентов с НАЖБП на разных этапах развития заболевания. The article discusses one of the most frequent hepatic pathologies, non-alcoholic fatty liver disease, and current concepts of its etiology, pathogenesis, diagnostic principles, and the latest approaches to conservative and surgical treatment. Pathophysiology of insulin resistance, metabolic syndrome, and other conditions clinically associated with non-alcoholic fatty liver disease are described. The authors deepened the insight into mechanisms of fibrosis development, up-to-date possibilities and limitations of imaging methods in diagnosis of the degree of steatosis and the stage of liver fibrosis, ultrasound, and serum markers. Clinical substantiation of the need to create an algorithm for examining and managing patients with non-alcoholic fatty liver disease at different stages of this condition and early verification of steatosis has an undoubted merit.
В статье представлены данные эпидемиологических исследований по распространенности симптомов гастроэзофагеальной рефлюксной болезни (ГЭРБ), факторы риска и проявления ГЭРБ. Особое внимание уделено индивидуальному терапевтическому подходу и выбору современного эффективного средства для лечения-ИПП декслансопразола.
Introduction. The term «functional disorders of the biliary tract and bile ducts» defines the conditions, which produce typical patterns of biliary pains in the absence of obvious signs of organic lesions of the gallbladder and bile ducts. The materials of the Rome IV consensus present the diagnostic criteria of their main types – functional disorders of the gall bladder and sphincter of Oddi. Vasilenko Clinic of Internal Diseases Propedeutics, Gastroenterology and Hepatology of the University Clinical Hospital No. 2 of Sechenov University carried out a noninterventional observational program to study the experience in using Trimedat® (trimebutine maleate) in the routine outpatient and inpatient practice in the treatment of patients with functional diseases of the biliary tract. Information partners of the program are the Russian Gastroenterological Association (RGA) and the Russian Society for the Study of the Liver (RSSL).Materials and methods. The program included patients of both sexes aged 18 to 65 years with ICD-10 diagnoses «spasm of the sphincter of Oddi» (K 83.4), «postcholecystectomy syndrome» (K 91.5), «other specified diseases of the gallbladder» (K 82.8) , «other specified diseases of the bile ducts» (K 83.8), «disorders of gallbladder and biliary tract in diseases classified elsewhere» (K 87.0), if the clinical picture was consistent with functional biliary disorders according to the Rome IV criteria and in cases when the doctor decided to prescribe Trimedat® therapy. Patients were observed for 28 ± 1 days. The dynamics of biliary pain and discomfort, as well as other symptoms (in particular, nausea, flatulence) were evaluated on the background of the therapy, using the Gastrointestinal Symptom Score Scale, in which the severity of each symptom is estimated by 7 grades (Alekseev N.Yu., 2006) with adding a section to evaluate the biliary disorders. In the presence of criteria for functional disorders of the gallbladder, an ultrasound control of the fraction of its discharge was carried out before and after the therapy.Results. 100 patients (33 (33%) men and 67 (67%) women, the average age 42.2 ± 13.2 years (18–65 years)) were enrolled in the program. In accordance with the Rome IV Consensus, the majority of patients (83 (83%)) had the functional disorders of GB; in 16 (16%) patients with the removed GB, the picture corresponded to the functional disorder of SO, one patient with kept GB was diagnosed with SO dysfunction. The treatment with Trimedate® at a standard dosage resulted in a decrease in the proportion of pain in the epigastric region (in the Scale section evaluating the biliary tract symptoms), the degree of nausea and bloating. Differences between the visits were estimated by the Friedman’s test, p <0.001. In addition, other sections of the scale also showed a decrease in indicators in scores. 79 patients underwent repeated ultrasound cholecystography at the end of treatment. It showed an increase in the fraction of GB emptying.Conclusions. The use of Trimedate® in patients with functional disorders of the gall bladder and sphincter of Oddi resulted in the reduction of the severity of the main symptoms - the severity of biliary pain, nausea, bloating. The patients with GB dysfunction showed an increase in the fraction of GB emptying.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
334 Leonard St
Brooklyn, NY 11211
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.